How did the survival of acute myeloid leukemia change over the last ten years in our unit?
INTRODUCTION: Acute myeloid leukemia (AML) is a hematological malignancy with high mortality rate. The treatment is especially challenging in patients older than 65 years, which is the large majority of those. For patients unfit for intensive chemotherapy regimens, only palliative cytoreduction and basic supportive care used to be the options in our unit. However, from 2018, the azacitidine-venetoclax combination has been a new therapeutic alternative. This treatment resulted in marked survival benefit in clinical trials, however, its impact on the daily clinical practice and the entire patient population is unclear.
OBJECTIVE: Our goal was to evaluate how the application of azacitidine-venetoclax changed the treatment and survival of AML patients in our practice.
METHOD: We retrospectively analyzed the available clinical data of all AML patients treated consecutively between January 1, 2011 and December 31, 2021 at the 3rd Department of Internal Medicine (from 2020 onward called Department of Internal Medicine and Hematology), examining their treatment depending on the time period of therapy (2011-2017 and 2018-2021). Patients with acute promyelocytic leukemia were excluded.
RESULTS: 423 patients were diagnosed during this period. The number of cases showed a marked increase: in the first 7 years of our study, 184 patients were diagnosed, while this rose to 239 during the subsequent 4 years. The median age of patients was 67.6 years, with more than 60% of patients aged over 65. An improving trend can be observed in the overall survival: between 2011 and 2017, the median overall survival was 4.8 ± 0.9 months, while between 2018 and 2021, it was 8.3 ± 1.4 months (p = 0.051). Moreover, in the case of patients over 65 there was a significant overall survival improvement: 3.1 ± 0.5 vs. 4.9 ± 0.6 months (p = 0,01). The main factor behind this improvement could be that a large proportion of over 65 patients previously only fit for supportive care could now be treated with azacitidine-venetoclax: the percentage of actively treated patients grew from 57.1% to 75.3% in the second period.
CONCLUSION: The survival of patients unfit for curative therapy and older than 65 showed a steady increase which can be attributed to the introduction of new therapeutic alternatives. Orv Hetil. 2023; 164(45): 1787-1794.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:164 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 164(2023), 45 vom: 12. Nov., Seite 1787-1794 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Hogyan változott az akut myeloid leukaemiás betegek túlélése a terápiás lehetőségek bővülésével az elmúlt 10 évben klinikánkon? |
|---|
| Beteiligte Personen: |
Gaál, Lilla [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.11.2023 Date Revised 22.11.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2023.32901 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364438355 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364438355 | ||
| 003 | DE-627 | ||
| 005 | 20231226095432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2023.32901 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364438355 | ||
| 035 | |a (NLM)37952177 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Gaál, Lilla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How did the survival of acute myeloid leukemia change over the last ten years in our unit? |
| 246 | 3 | 3 | |a Hogyan változott az akut myeloid leukaemiás betegek túlélése a terápiás lehetőségek bővülésével az elmúlt 10 évben klinikánkon? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.11.2023 | ||
| 500 | |a Date Revised 22.11.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Acute myeloid leukemia (AML) is a hematological malignancy with high mortality rate. The treatment is especially challenging in patients older than 65 years, which is the large majority of those. For patients unfit for intensive chemotherapy regimens, only palliative cytoreduction and basic supportive care used to be the options in our unit. However, from 2018, the azacitidine-venetoclax combination has been a new therapeutic alternative. This treatment resulted in marked survival benefit in clinical trials, however, its impact on the daily clinical practice and the entire patient population is unclear | ||
| 520 | |a OBJECTIVE: Our goal was to evaluate how the application of azacitidine-venetoclax changed the treatment and survival of AML patients in our practice | ||
| 520 | |a METHOD: We retrospectively analyzed the available clinical data of all AML patients treated consecutively between January 1, 2011 and December 31, 2021 at the 3rd Department of Internal Medicine (from 2020 onward called Department of Internal Medicine and Hematology), examining their treatment depending on the time period of therapy (2011-2017 and 2018-2021). Patients with acute promyelocytic leukemia were excluded | ||
| 520 | |a RESULTS: 423 patients were diagnosed during this period. The number of cases showed a marked increase: in the first 7 years of our study, 184 patients were diagnosed, while this rose to 239 during the subsequent 4 years. The median age of patients was 67.6 years, with more than 60% of patients aged over 65. An improving trend can be observed in the overall survival: between 2011 and 2017, the median overall survival was 4.8 ± 0.9 months, while between 2018 and 2021, it was 8.3 ± 1.4 months (p = 0.051). Moreover, in the case of patients over 65 there was a significant overall survival improvement: 3.1 ± 0.5 vs. 4.9 ± 0.6 months (p = 0,01). The main factor behind this improvement could be that a large proportion of over 65 patients previously only fit for supportive care could now be treated with azacitidine-venetoclax: the percentage of actively treated patients grew from 57.1% to 75.3% in the second period | ||
| 520 | |a CONCLUSION: The survival of patients unfit for curative therapy and older than 65 showed a steady increase which can be attributed to the introduction of new therapeutic alternatives. Orv Hetil. 2023; 164(45): 1787-1794 | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a akut myeloid leukaemia | |
| 650 | 4 | |a azacitidin | |
| 650 | 4 | |a azacitidine | |
| 650 | 4 | |a real-world | |
| 650 | 4 | |a survival | |
| 650 | 4 | |a túlélés | |
| 650 | 4 | |a venetoclax | |
| 650 | 4 | |a venetoklax | |
| 650 | 4 | |a ’real-world’ | |
| 650 | 7 | |a Azacitidine |2 NLM | |
| 650 | 7 | |a M801H13NRU |2 NLM | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 650 | 7 | |a Bridged Bicyclo Compounds, Heterocyclic |2 NLM | |
| 700 | 1 | |a Ruff, Eszter |e verfasserin |4 aut | |
| 700 | 1 | |a Wiedemann, Ádám |e verfasserin |4 aut | |
| 700 | 1 | |a Svorenj, Szabolcs |e verfasserin |4 aut | |
| 700 | 1 | |a Szita, Virág Réka |e verfasserin |4 aut | |
| 700 | 1 | |a Tóth, András Dávid |e verfasserin |4 aut | |
| 700 | 1 | |a Masszi, András |e verfasserin |4 aut | |
| 700 | 1 | |a Horváth, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Szombath, Gergely |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Zsolt |e verfasserin |4 aut | |
| 700 | 1 | |a Várkonyi, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Benedek, Szabolcs |e verfasserin |4 aut | |
| 700 | 1 | |a Farkas, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Bödör, Csaba |e verfasserin |4 aut | |
| 700 | 1 | |a Masszi, Tamás |e verfasserin |4 aut | |
| 700 | 1 | |a Varga, Gergely |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 164(2023), 45 vom: 12. Nov., Seite 1787-1794 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:164 |g year:2023 |g number:45 |g day:12 |g month:11 |g pages:1787-1794 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2023.32901 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2023 |e 45 |b 12 |c 11 |h 1787-1794 | ||